GSK3 takes centre stage more than 20 years after its discovery.

Identified originally as a regulator of glycogen metabolism, glycogen synthase kinase-3 (GSK3) is now a well-established component of the Wnt signalling pathway, which is essential for setting up the entire body pattern during embryonic development. It may also play important roles in protein synthesis, cell proliferation, cell differentiation, microtubule dynamics and cell motility by phosphorylating initiation factors, components of the cell-division cycle, transcription factors and proteins involved in microtubule function and cell adhesion. Generation of the mouse knockout of GSK3beta, as well as studies in neurons, also suggest an important role in apoptosis. The substrate specificity of GSK3 is unusual in that efficient phosphorylation of many of its substrates requires the presence of another phosphorylated residue optimally located four amino acids C-terminal to the site of GSK3 phosphorylation. Recent experiments, including the elucidation of its three-dimensional structure, have enhanced our understanding of the molecular basis for the unique substrate specificity of GSK3. Insulin and growth factors inhibit GSK3 by triggering its phosphorylation, turning the N-terminus into a pseudosubstrate inhibitor that competes for binding with the 'priming phosphate' of substrates. In contrast, Wnt proteins inhibit GSK3 in a completely different way, by disrupting a multiprotein complex comprising GSK3 and its substrates in the Wnt signalling pathway, which do not appear to require a 'priming phosphate'. These latest findings have generated an enormous amount of interest in the development of drugs that inhibit GSK3 and which may have therapeutic potential for the treatment of diabetes, stroke and Alzheimer's disease.

[1]  G. Drewes,et al.  Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau , 1992, FEBS letters.

[2]  Marty W. Mayo,et al.  WNT-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor–Mediated Transcription , 2001, The Journal of cell biology.

[3]  Christoph W. Turck,et al.  Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3 , 1997, Science.

[4]  Y. Masui,et al.  Lithium-induced respecification of pattern in Xenopus laevis embryos , 1986, Nature.

[5]  R. Benarous,et al.  The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell , 1999, Current Biology.

[6]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation , 2001, Oncogene.

[7]  V. Pantesco,et al.  Drosophila shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and act downstream of Notch , 1993, Nature.

[8]  E. Fuchs,et al.  Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. , 1999, Development.

[9]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[10]  C. W. Scott,et al.  Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Neal,et al.  Glycogen Synthase Kinase-3 Inhibits the DNA Binding Activity of NFATc* , 2001, The Journal of Biological Chemistry.

[12]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[13]  J. Woodgett,et al.  Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation. , 1993, The EMBO journal.

[14]  E. Gulve,et al.  Stimulatory effect of lithium on glucose transport in rat adipocytes is not mediated by elevation of IP1. , 1998, American journal of physiology. Endocrinology and metabolism.

[15]  F. Soncin,et al.  Transcriptional Activity of Heat Shock Factor 1 at 37 oC Is Repressed through Phosphorylation on Two Distinct Serine Residues by Glycogen Synthase Kinase 3α and Protein Kinases Cα and Cζ* , 1998, The Journal of Biological Chemistry.

[16]  A. Kimmel,et al.  GSK3, a master switch regulating cell-fate specification and tumorigenesis. , 2000, Current opinion in genetics & development.

[17]  G. Johnson,et al.  Transient Increases in Intracellular Calcium Result in Prolonged Site-selective Increases in Tau Phosphorylation through a Glycogen Synthase Kinase 3β-dependent Pathway* , 1999, The Journal of Biological Chemistry.

[18]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[19]  R. Garofalo,et al.  Inhibition of Glycogen-synthase Kinase 3 Stimulates Glycogen Synthase and Glucose Transport by Distinct Mechanisms in 3T3-L1 Adipocytes* , 2000, The Journal of Biological Chemistry.

[20]  S. Dedhar,et al.  Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Kimelman,et al.  Role of Glycogen Synthase Kinase-3β in Neuronal Apoptosis Induced by Trophic Withdrawal , 2000, The Journal of Neuroscience.

[22]  P. Salinas,et al.  Inhibition of GSK-3 β leading to the loss of phosphorylated MAP-1 B is an early event in axonal remodelling induced by WNT-7 a or lithium , 1998 .

[23]  N. Perrimon,et al.  wingless signaling acts through zeste-white 3, the drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate , 1992, Cell.

[24]  Mark P. Mattson,et al.  Apoptosis in neurodegenerative disorders , 2000, Nature Reviews Molecular Cell Biology.

[25]  J. Woodgett,et al.  cDNA cloning and properties of glycogen synthase kinase-3. , 1991, Methods in enzymology.

[26]  J. Lautenberger,et al.  Sequence curiosity in v-myc oncogene , 1985, Nature.

[27]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[28]  D. Alessi,et al.  Mitogen‐ and stress‐activated protein kinase‐1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB , 1998, The EMBO journal.

[29]  S. Byers,et al.  Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest , 1999, Journal of Cell Biology.

[30]  M. Bienz,et al.  EGF receptor/Rolled MAP kinase signalling protects cells against activated Armadillo in the Drosophila eye , 2001, EMBO reports.

[31]  P. Cohen,et al.  Insulin activates protein kinase B, inhibits glycogen synthase kinase‐3 and activates glycogen synthase by rapamycin‐insensitive pathways in skeletal muscle and adipose tissue , 1997, FEBS letters.

[32]  S. Hsu,et al.  Glycogen Synthase Kinase-3β Regulates Presenilin 1 C-terminal Fragment Levels* , 2001, The Journal of Biological Chemistry.

[33]  Ming-tao Li,et al.  Cyclic AMP Promotes Neuronal Survival by Phosphorylation of Glycogen Synthase Kinase 3β , 2000, Molecular and Cellular Biology.

[34]  E. Krebs,et al.  Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. , 1999, Diabetes.

[35]  S. Pierce,et al.  Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3. , 1995, Development.

[36]  Philip R. Cohen,et al.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. , 2001, The Biochemical journal.

[37]  T. Graf,et al.  Quail embryo fibroblasts transformed by four v‐myc‐containing virus isolates show enhanced proliferation but are non tumorigenic. , 1983, The EMBO journal.

[38]  Hideki Yamamoto,et al.  Phosphorylation of Axin, a Wnt Signal Negative Regulator, by Glycogen Synthase Kinase-3β Regulates Its Stability* , 1999, The Journal of Biological Chemistry.

[39]  L. Williams,et al.  Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. ter Haar,et al.  Structure of GSK3beta reveals a primed phosphorylation mechanism. , 2001, Nature structural biology.

[41]  P. Roach,et al.  Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. , 1987, The Journal of biological chemistry.

[42]  A. Berns,et al.  Activation of a novel proto‐oncogene, Frat1, contributes to progression of mouse T‐cell lymphomas , 1997, The EMBO journal.

[43]  W. Bodmer,et al.  Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Nakayama,et al.  Common Pathway for the Ubiquitination of IκBα, IκBβ, and IκBε Mediated by the F-Box Protein FWD1* , 1999, The Journal of Biological Chemistry.

[45]  J C Reed,et al.  Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. , 2001, Molecular cell.

[46]  P. Cohen,et al.  How does insulin stimulate glycogen synthesis? , 1978, Biochemical Society symposium.

[47]  R. Stephens,et al.  The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth , 1999, Oncogene.

[48]  Akira Kikuchi,et al.  Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin , 1998 .

[49]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Jope,et al.  Glycogen Synthase Kinase-3β Facilitates Staurosporine- and Heat Shock-induced Apoptosis , 2000, The Journal of Biological Chemistry.

[51]  J. Woodgett,et al.  Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. , 1994, Oncogene.

[52]  M. Raffeld,et al.  Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. , 1994, Cancer research.

[53]  G. Borasio,et al.  Survival-Promoting Activity of Inhibitors of Cyclin-Dependent Kinases on Primary Neurons Correlates with Inhibition of c-Jun Kinase-1 , 1997, Neurobiology of Disease.

[54]  D. Fisher,et al.  Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. , 2000, Human molecular genetics.

[55]  A. M. Arias,et al.  Wnt signalling: pathway or network? , 1999, Current opinion in genetics & development.

[56]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[57]  J. Woodgett,et al.  Identification of multifunctional ATP-citrate lyase kinase as the alpha-isoform of glycogen synthase kinase-3. , 1992, The Biochemical journal.

[58]  P. Cohen,et al.  Phosphorylation of the skeletal muscle glycogen‐targetting subunit of protein phosphatase 1 in response to adrenaline in vivo , 2000, FEBS letters.

[59]  J Mao,et al.  Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt‐mediated regulation of LEF‐1 , 1999, The EMBO journal.

[60]  P. Cohen,et al.  Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. , 2005, European journal of biochemistry.

[61]  F. Watt,et al.  beta-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. , 1999, Development.

[62]  Jörg Stappert,et al.  β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .

[63]  Harold E. Varmus,et al.  Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos , 1995, Nature.

[64]  S. Sokol,et al.  Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and β-catenin , 1998, Current Biology.

[65]  S. Orsulic,et al.  An in vivo structure-function study of armadillo, the beta-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling , 1996, The Journal of cell biology.

[66]  J. Mester,et al.  Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Byers,et al.  Exogenous Expression of b -Catenin Regulates Contact Inhibition, Anchorage-independent Growth, Anoikis, and Radiation-induced Cell Cycle Arrest , 1999 .

[68]  B G Benson,et al.  Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. , 2001, Science.

[69]  A. Hyman,et al.  Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3β phosphorylation , 2001, Current Biology.

[70]  P. Cohen,et al.  A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. , 2001, Molecular Cell.

[71]  B. Gumbiner,et al.  Binding to cadherins antagonizes the signaling activity of beta-catenin during axis formation in Xenopus , 1996, The Journal of cell biology.

[72]  J. Woodgett,et al.  ATP citrate-lyase and glycogen synthase kinase-3 beta in 3T3-L1 cells during differentiation into adipocytes. , 1994, The Biochemical journal.

[73]  P. Cohen,et al.  PDK1, one of the missing links in insulin signal transduction? 1 , 1997, FEBS letters.

[74]  F. McCormick,et al.  Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling* , 2000, The Journal of Biological Chemistry.

[75]  P. Cohen,et al.  A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐catenin , 1999, FEBS letters.

[76]  H. Sheng,et al.  Oncogenic Ras-mediated Cell Growth Arrest and Apoptosis are Associated with Increased Ubiquitin-dependent Cyclin D1 Degradation* , 2000, The Journal of Biological Chemistry.

[77]  J. Behrens,et al.  Biochemical interactions in the wnt pathway. , 2000, Biochimica et biophysica acta.

[78]  J. Woodgett,et al.  Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. , 1993, Oncogene.

[79]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[80]  O. MacDougald,et al.  Growth Hormone Regulates Phosphorylation and Function of CCAAT/Enhancer-binding Protein β by Modulating Akt and Glycogen Synthase Kinase-3* , 2001, The Journal of Biological Chemistry.

[81]  A. Kimmel,et al.  The Novel Tyrosine Kinase ZAK1 Activates GSK3 to Direct Cell Fate Specification , 1999, Cell.

[82]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.

[83]  P. Roach,et al.  A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. , 1994, The Journal of biological chemistry.

[84]  J. Woodgett,et al.  Glycogen Synthase Kinase 3β Negatively Regulates Both DNA-binding and Transcriptional Activities of Heat Shock Factor 1* , 2000, The Journal of Biological Chemistry.

[85]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.

[86]  G L Snyder,et al.  Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? , 2001, The Journal of biological chemistry.

[87]  Tony Hunter,et al.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity , 1991, Cell.

[88]  R. Goold,et al.  Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. , 1999, Journal of cell science.

[89]  Brendan D. Price,et al.  Sequential Phosphorylation by Mitogen-activated Protein Kinase and Glycogen Synthase Kinase 3 Represses Transcriptional Activation by Heat Shock Factor-1* , 1996, The Journal of Biological Chemistry.

[90]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[91]  Hideki Yamamoto,et al.  Axin, a Negative Regulator of the Wnt Signaling Pathway, Directly Interacts with Adenomatous Polyposis Coli and Regulates the Stabilization of β-Catenin* , 1998, The Journal of Biological Chemistry.

[92]  P. Lochhead,et al.  Inhibition of GSK-3 Selectively Reduces Glucose-6-Phosphatase and Phosphoenolpyruvate Carboxykinase Gene Expression , 2001 .

[93]  D. M. Ferkey,et al.  Interaction among Gsk-3, Gbp, Axin, and APC in Xenopus Axis Specification , 2000, The Journal of cell biology.

[94]  P. Cohen,et al.  The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells , 2000, Current Biology.

[95]  Philip R. Cohen,et al.  Further evidence that the inhibition of glycogen synthase kinase‐3β by IGF‐1 is mediated by PDK1/PKB‐induced phosphorylation of Ser‐9 and not by dephosphorylation of Tyr‐216 , 1997, FEBS letters.

[96]  O. MacDougald,et al.  Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase. , 1999, Molecular and cellular biology.

[97]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[98]  J. Massagué,et al.  Insulin control of rat hepatocyte glycogen synthase and phosphorylase in the absence of glucose , 1977, FEBS letters.

[99]  P. Polakis,et al.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. , 1998, Current biology : CB.

[100]  Raymond L. White,et al.  Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. , 2001, Molecular cell.

[101]  E. Krebs,et al.  Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[102]  R. Kemler,et al.  Curbing the nuclear activities of β‐catenin , 2000 .

[103]  Philip R. Cohen,et al.  MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells , 2000, FEBS letters.

[104]  Paul Polakis,et al.  Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly , 1996, Science.

[105]  D. Moller,et al.  New approaches in the treatment of type 2 diabetes. , 2000, Current opinion in chemical biology.

[106]  J. Graff,et al.  Casein kinase I transduces Wnt signals , 1999, Nature.

[107]  M. Goedert.  The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. , 2001, Current opinion in genetics & development.

[108]  J L Cleveland,et al.  Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. , 2000, Genes & development.

[109]  S. Lomvardas,et al.  A GSK3beta phosphorylation site in axin modulates interaction with beta-catenin and Tcf-mediated gene expression. , 1999, Biochemical and biophysical research communications.

[110]  E. Shooter,et al.  Apoptosis of Central and Peripheral Neurons Can Be Prevented with Cyclin‐Dependent Kinase/Mitogen‐Activated Protein Kinase Inhibitors , 1998, Journal of neurochemistry.

[111]  N. Turner,et al.  Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. , 1998, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[112]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.

[113]  C. Burant,et al.  Phosphorylation of Insulin Receptors Solubilized from Rat Skeletal Muscle , 1984, Diabetes.

[114]  I. Magrath,et al.  Point mutations in the c–Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas , 1993, Nature Genetics.

[115]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[116]  A. Reith,et al.  Selective small‐molecule inhibitors of glycogen synthase kinase‐3 activity protect primary neurones from death , 2001, Journal of neurochemistry.

[117]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[118]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[119]  Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Identification of the sites phosphorylated by casein kinase-I. , 1982, European journal of biochemistry.

[120]  P. Cohen,et al.  Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. , 1999, FEBS letters.

[121]  James R. Woodgett,et al.  Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells , 1996, Current Biology.

[122]  A. McMahon,et al.  Wnt-1-dependent regulation of local E-cadherin and alpha N-catenin expression in the embryonic mouse brain. , 1994, Development.

[123]  R. Roth,et al.  Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway* , 1999, The Journal of Biological Chemistry.

[124]  G. Cooper,et al.  Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway* , 1998, The Journal of Biological Chemistry.

[125]  Philip R. Cohen,et al.  The development and therapeutic potential of protein kinase inhibitors. , 1999, Current opinion in chemical biology.

[126]  P. Cohen,et al.  Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. , 1998, Chemistry & biology.

[127]  Laurence H. Pearl,et al.  Crystal Structure of Glycogen Synthase Kinase 3β Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition , 2001, Cell.

[128]  J. Auwerx,et al.  Negative regulation of Jun/AP-1: conserved function of glycogen synthase kinase 3 and the Drosophila kinase shaggy. , 1993, Oncogene.

[129]  M. Taketo,et al.  Intestinal polyposis in mice with a dominant stable mutation of the β‐catenin gene , 1999, The EMBO journal.

[130]  H. Varmus,et al.  Casein kinase 2 associates with and phosphorylates Dishevelled , 1997, The EMBO journal.

[131]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[132]  Y. Ihara,et al.  Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. , 1993, Journal of neurochemistry.

[133]  C. Proud,et al.  Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. , 1993, The Biochemical journal.

[134]  David S. Park,et al.  G1/S Cell Cycle Blockers and Inhibitors of Cyclin-Dependent Kinases Suppress Camptothecin-Induced Neuronal Apoptosis , 1997, The Journal of Neuroscience.

[135]  R. Nusse,et al.  A Versatile Transcriptional Effector of Wingless Signaling , 1997, Cell.

[136]  J. Ávila,et al.  Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons , 1997, FEBS letters.